DIVIS LABORATORIES
|
DIVIS LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 60.38 | 68.83 | 111.53 | 74.75 | 51.86 |
| CEPS(Rs) | 74.64 | 81.77 | 123.26 | 84.38 | 58.87 |
| DPS(Rs) | 30.00 | 30.00 | 30.00 | 20.00 | 16.00 |
| Book NAV/Share(Rs) | 512.11 | 481.77 | 441.82 | 350.15 | 275.38 |
| Tax Rate(%) | 26.03 | 23.01 | 19.63 | 25.57 | 24.34 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 27.96 | 30.30 | 43.18 | 40.92 | 33.41 |
| EBIT Margin(%) | 27.46 | 30.32 | 41.00 | 38.16 | 33.48 |
| Pre Tax Margin(%) | 27.41 | 30.30 | 40.98 | 38.13 | 33.35 |
| PAT Margin (%) | 20.28 | 23.33 | 32.94 | 28.38 | 25.23 |
| Cash Profit Margin (%) | 25.07 | 27.71 | 36.40 | 32.04 | 28.64 |
| Performance Ratios | |||||
| ROA(%) | 10.39 | 12.37 | 22.77 | 19.07 | 15.11 |
| ROE(%) | 12.15 | 14.89 | 28.16 | 23.90 | 19.30 |
| ROCE(%) | 16.46 | 19.36 | 35.06 | 32.07 | 25.36 |
| Asset Turnover(x) | 0.51 | 0.53 | 0.69 | 0.67 | 0.60 |
| Sales/Fixed Asset(x) | 1.20 | 1.30 | 1.74 | 1.70 | 1.77 |
| Working Capital/Sales(x) | 0.94 | 0.95 | 1.26 | 1.38 | 1.45 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.83 | 0.77 | 0.57 | 0.59 | 0.56 |
| Receivable days | 91.33 | 98.42 | 83.26 | 80.66 | 86.18 |
| Inventory Days | 143.02 | 136.04 | 100.99 | 104.66 | 121.62 |
| Payable days | 92.50 | 93.12 | 95.88 | 106.32 | 93.73 |
| Valuation Parameters | |||||
| PER(x) | 56.92 | 41.05 | 39.49 | 48.56 | 38.33 |
| PCE(x) | 46.04 | 34.56 | 35.73 | 43.02 | 33.76 |
| Price/Book(x) | 6.71 | 5.87 | 9.97 | 10.37 | 7.22 |
| Yield(%) | 0.87 | 1.06 | 0.68 | 0.55 | 0.81 |
| EV/Net Sales(x) | 11.10 | 9.10 | 12.73 | 13.52 | 9.76 |
| EV/Core EBITDA(x) | 34.22 | 26.04 | 28.54 | 32.22 | 26.17 |
| EV/EBIT(x) | 40.19 | 29.81 | 30.95 | 35.31 | 28.84 |
| EV/CE(x) | 6.42 | 5.54 | 7.80 | 8.27 | 5.59 |
| M Cap / Sales | 11.61 | 9.64 | 13.05 | 13.83 | 9.78 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 1.00 | -13.31 | 28.56 | 29.20 | 9.06 |
| Core EBITDA Growth(%) | -6.23 | -32.10 | 36.71 | 45.25 | -0.78 |
| EBIT Growth(%) | -8.60 | -35.67 | 38.13 | 46.07 | -1.78 |
| PAT Growth(%) | -12.28 | -38.39 | 49.19 | 44.15 | 1.76 |
| EPS Growth(%) | -12.28 | -38.28 | 49.19 | 44.15 | 1.76 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | - |
| Current Ratio(x) | 5.78 | 6.34 | 3.92 | 3.93 | 3.06 |
| Quick Ratio(x) | 3.97 | 4.39 | 2.76 | 2.69 | 2.04 |
| Interest Cover(x) | 541.75 | 1,185.50 | 1,842.75 | 1,270.54 | 255.83 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of DIVIS LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| DIVIS LABORATORIES | ₹148,040.1 Cr | 0% | -9.2% | 61.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹418,228.0 Cr | -2.4% | -7.2% | 27.2% | Stock Analytics | |
| CIPLA | ₹119,474.0 Cr | 6% | -3.8% | 10.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,599.0 Cr | 1.7% | -11.4% | 2.2% | Stock Analytics | |
| MANKIND PHARMA | ₹100,540.0 Cr | -0.9% | -16% | 21% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹97,604.7 Cr | 5.2% | -2.1% | 26.1% | Stock Analytics | |
DIVIS LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DIVIS LABORATORIES | 0% |
-9.2% |
61.5% |
| SENSEX | 1.7% |
-1.3% |
7.7% |
You may also like the below Video Courses
